Close this search box.

SBRT for Oligometastatic Disease: an Overview of Current Evidence and Future Directions

May 25, 2023

If you are unable to access ON24, please click here.

The role of SBRT in the treatment of oligometastatic and oligo-progressive disease is evolving rapidly. This webinar will review the management of oligometastatic disease and highlight recent data that helps define the appropriate use of SBRT for oligometastases. Additionally, technical considerations will be discussed in terms of treatment planning, concurrent systemic therapy and management of acute and late toxicity.

Todd Carpenter, M.D.                              

Associate Director of Clinical Operations, Radiation Oncology, NYU Langone Hospital- Long Island, New York, USA

Dr. Todd J. Carpenter is a radiation oncologist in New York. He received his medical degree from the State University of New York Downstate Medical Center College of Medicine and completed his residency at Icahn School of Medicine at Mount Sinai, Radiation Oncology in 2015.

Dr. Carpenter is an internationally recognized user of the CyberKnife® System and is extensively involved in research furthering the application of stereotactic and image-guided radiotherapy and has published several articles.

Moderator: Barbara Alicja Jereczek-Fossa M.D., Ph.D.

Full Professor of Radiation Oncology, University of Milan, Italy             

Head of the Department of Radiation Oncology, European Institute of Oncology, Milan, Italy 

Barbara Alicja Jereczek-Fossa, M.D., Ph.D., is currently Full Professor of Radiation Oncology at the Department of Oncology and Hemato-oncology at the University of Milan and Chair of the Department of Radiation Oncology at the European Institute of Oncology IRCCS (IEO), Milan, Italy.

Prof. Jereczek-Fossa is actively involved in numerous educational and research activities, both at national and international level. She is an active member of numerous scientific societies, committees and editorial boards and regularly participates in scientific meetings, consensus (including Advance Prostate Cancer Consensus Conference) and guidelines task-forces.

Prof. Jereczek-Fossa is a Chair of the National Societies Committee of the European Society of Radiotherapy and Oncology (ESTRO) and coordinates the Education Committee of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). 

Her research regards mainly urological and breast malignancies, innovation in radiation oncology (SBRT, IGRT, proton therapy etc.), combined drug-radiation treatment, AI & radiomics.

Prof. Jereczek-Fossa is author of over 400 peer-reviewed scientific papers and 7 book chapters and she is in the Top Italian Scientists list – TIS list.

Her total impact factor (IF) of 1628.123 (mean IF: *: 3.786/article) and her H-index, according to Google Scholar, is 49 (Author ID: 7004306533; ORCID: